Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aphria Inc. (APHA) Stock Moves -0.26%: What You Should Know
by Zacks Equity Research
In the latest trading session, Aphria Inc. (APHA) closed at $3.82, marking a -0.26% move from the previous day.
Implied Volatility Surging for Aphria (APHA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.
Aphria Inc. (APHA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aphria Inc. (APHA) delivered earnings and revenue surprises of 0.00% and -9.42%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
by Zacks Equity Research
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
by Zacks Equity Research
Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.
Aphria Inc. (APHA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aphria Inc. (APHA) closed at $4.84 in the latest trading session, marking a +1.58% move from the prior day.
Earnings Preview: Aphria Inc. (APHA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Aphria Inc. (APHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Apple, Aphria, Global Payments, NetEase and Qorvo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Aphria, Global Payments, NetEase and Qorvo
Here're the Top Stock Trades for 2020
by Tirthankar Chakraborty
Investors shouldn't steer clear of stocks this year. In fact, one should look for potential avenues to invest as the economy gathers momentum. Let's take a look --
The Zacks Analyst Blog Highlights: CNXM, ONDK, ECOM, APHA and BIDU
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CNXM, ONDK, ECOM, APHA and BIDU
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Ride the Cannabis Wave With These 3 Stocks
by Urmimala Biswas
Here we discuss three best stocks in the emerging cannabis space.
Dog Stocks of 2019 to Return 20%+ in 2020: 5 Picks
by Tirthankar Chakraborty
We have highlighted five stocks that were lousy in 2019 but could return 20% or more in 2020.
The Zacks Analyst Blog Highlights: Innovative Industrial Properties, Aphria, Square and GW Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Innovative Industrial Properties, Aphria, Square and GW Pharmaceuticals
4 Marijuana Stocks to Play the Green Rush in 2020
by Tirthankar Chakraborty
Marijuana legalization has started to ramp-up in several U.S. states. What's more, legalization of marijuana in the state of Illinois in January could bring positive tidings for the marijuana industry.
Top Ranked Momentum Stocks to Buy for December 19th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 19th.
New Strong Buy Stocks for December 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Aphria Inc. (APHA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aphria Inc. (APHA) closed the most recent trading day at $4.74, moving +1.94% from the previous trading session.
Aphria Inc. (APHA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aphria Inc. (APHA) closed the most recent trading day at $4.55, moving -0.22% from the previous trading session.
Implied Volatility Surging for Aphria (APHA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.
Marijuana ETFs Bounce Back: Can the Rally Last?
by Sanghamitra Saha
Passing of a legalization bill by a U.S. congressional committee boosted the battered marijuana ETF space lately.
Can Bill Hopes Relieve Earnings-Induced Pain in Pot ETFs?
by Sanghamitra Saha
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?
by Benjamin Rains
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed's (RMD) performance.